Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.89 USD
Change Today +0.10 / 1.28%
Volume 943.4K
INFI On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/12/14 - $18.25
52 Week Low
10/8/15 - $7.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

195 Employees
Last Reported Date: 02/24/15

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $568.5K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $390.0K
President of Research & Development
Total Annual Compensation: $479.5K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $381.0K
Compensation as of Fiscal Year 2014.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. to Provide an Update on the Clinical Development Program and Commercial Overview for Duvelisib

Infinity Pharmaceuticals, Inc. announced that it will provide an update on the clinical development program and commercial overview for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and discuss the company's immuno-oncology development candidate, IPI-549, at its Research and Development (R&D) Day this morning from 8:00am (ET) to 11:45am (ET) in New York City. During today's presentations, Infinity will review its anticipated timelines for the development and commercialization of duvelisib. The company recently announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL), and topline data from this study are anticipated in the third quarter of 2016. Infinity will also review the IPI-549 data presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and discuss the planned Phase 1 study for IPI-549 in solid tumors.

Infinity Pharmaceuticals, Inc. Announces Enrollment of 120th Patient in Phase 2 DYNAMO Study Evaluating Duvelisib in Indolent Non-Hodgkin Lymphoma

Infinity Pharmaceuticals, Inc. announced that the 120th patient has been enrolled in DYNAMO, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL) evaluating the safety and efficacy of duvelisib an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. This enrollment achievement triggers a $130 million milestone payment from AbbVie Inc. Infinity expects to report topline data from DYNAMO in the third quarter of 2016. DYNAMO is a global, Phase 2 open-label, single-arm, monotherapy study of duvelisib (25 mg BID) in 120 patients with iNHL whose disease is refractory to rituximab and to either chemotherapy or radioimmunotherapy. The primary endpoint is overall response rate.

Infinity Pharmaceuticals, Inc. - Special Call

To review the clinical development program for duvelisib and discuss the company's newest development candidate, IPI549


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $7.89 USD +0.10

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.96 USD -0.02
CTI BioPharma Corp $1.64 USD +0.01
Cytokinetics Inc $6.98 USD -0.05
Evotec AG €4.12 EUR 0.00
GlaxoSmithKline SAE £10.30 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at